Cambrex Milan Marks 80 Years of Excellence with New R&D Facility Investment

Cambrex Celebrates 80th Anniversary with Investment in New R&D Facility

Cambrex, a prominent global player in contract development and manufacturing organization (CDMO), has commenced construction on a new research and development facility at its Milan site, marking a significant milestone in the company's long-standing commitment to the pharmaceutical sector. This new $30 million investment not only signifies Cambrex's dedication to quality and precision in drug development but also aims to enhance its analytical and process development capabilities.

As Cambrex celebrates its 80th anniversary this year, the company reflects on its impressive legacy in supporting pharmaceutical manufacturing and development for an expansive global client base. The new R&D facility is designed to meet the increasing demands of complex small molecule therapies, positioning Cambrex at the forefront of the market.

Scheduled for completion in the latter half of 2027, the expansion is set to include advanced analytical development attributes that will bolster the existing operations. In addition, Cambrex has acquired additional land adjacent to their current facility to accommodate future growth, ensuring ongoing innovation for years to come.

Claudio Russolo, the Chief Operating Officer of Cambrex, emphasized the importance of this expansion: “Breaking ground on this new facility is a testament to the enduring legacy and expertise of our Milan team. For 80 years, this site has been a cornerstone of pharmaceutical manufacturing in Europe. With this expansion, we are investing not only in new technologies and capabilities, but in the future of our people and our partners.”

This substantial investment highlights Cambrex's commitment to scientific excellence and their ongoing efforts to adapt to the evolving pharmaceutical landscape. The new capabilities will enable Cambrex to better serve its clients by addressing more complex therapeutic challenges in the market.

The Cambrex Profarmico Milano site has a distinguished history of innovation, underpinned by a skilled workforce dedicated to advancing health solutions globally. As the company moves forward into its next chapter, it aims to strengthen its reputation further, leveraging a rich history of expertise paired with modern advancements in drug manufacturing.

About Cambrex:
Cambrex is a renowned CDMO with over 45 years of experience, specializing in drug substance development and manufacturing across the complete lifecycle of pharmaceuticals. With a team of around 2,000 professionals based in Europe and North America, Cambrex offers a comprehensive suite of drug substance technologies and capabilities, including controlled substances, peptide synthesis, biocatalysis, and much more to satisfy the intricate demands of the pharmaceutical industry.

In conclusion, Cambrex's investment in the new R&D facility not only marks a celebratory occasion of its 80-year existence but also reinforces its essential role in the pharmaceutical manufacturing industry, demonstrating a robust commitment to innovation and excellence.